menu
close
This website is intended for UK Healthcare Professionals only. Not a UK Healthcare Professional? Click here
menu
close
menu
close

The adverse event reporting information can be found by scrolling to the bottom of this page.

 

VEOZA (fezolinetant) is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.1

VMS are also known as hot flushes* and night sweats.2

Homepage banner

VEOZA directly targets a source of VMS-specific neurons in the hypothalamus1

Watch the mechanism of action (MOA)

MOA

Watch the mechanism of action (MOA)

VEOZA is the first-in-class selective neurokinin 3 (NK3) receptor antagonist to be licensed. It blocks neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron, which is postulated to restore the balance in KNDy neuronal activity in the thermoregulatory centre of the hypothalamus.1,3,4

Put VEOZA to work for your appropriate menopause patients suffering from moderate to severe VMS
Put VEOZA to work for your appropriate menopause patients suffering from moderate to severe VMS
EFFICACY AND SAFETY

EFFICACY AND SAFETY

Achieve fewer and less severe VMS episodes with VEOZA vs. placebo

VEOZA demonstrated statistically significant reductions from baseline in VMS frequency and severity at Weeks 4 and 12 vs. placebo1

Sign up for VEOZA updates and product information

*Hot flushes are also known as hot flashes.3
 

KNDy: kisspeptin/neurokinin B/dynorphin, MOA: mechanism of action, NK3: neurokinin 3, NKB: neurokinin B, VMS: vasomotor symptoms.


REFERENCES: 1. VEOZA Summary of Product Characteristics. 2. Thurston RC. Vasomotor symptoms. In: Crandall CJ, Bachman GA, Faubion SS, et al., eds. Menopause Practice: A Clinician’s Guide. 6th ed. Pepper Pike, OH: The North American Menopause Society, 2019:43-55. 3. Depypere H, Lademacher C, Siddiqui E, Fraser GL. Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opin Investig Drugs 2021;30(7):681-94. 4. Jayasena CN, Comninos AN, Stefanopoulou E, et al. Neurokinin B administration induces hot flushes in women. Sci Rep (Epub) 02-16-2015.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Astellas Pharma Ltd. on 0800 783 5018.

MAT-GB-VEO-2024-00254. February 2025